Delivery Order SPE2DB22D2206-SPE2DB25FJF24
- Not listed
- The Defense Logistics Agency awarded a $10,662.57 delivery order to AmerisourceBergen Drug Corp for TAGRISSO 80 mg tablets (30-count units) on September 5, 2025, with an ultimate completion date of September 26, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. TAGRISSO is a targeted cancer therapy used in the treatment of non-small cell lung cancer, reflecting...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $21,325.14 for TAGRISSO 80 mg tablets (30-count units) on July 31, 2025, with an ultimate completion date of August 21, 2025. This firm fixed-price, competitively awarded delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. TAGRISSO is a prescription oncology medication used primarily in the treatment of...
- The Defense Logistics Agency awarded a delivery order valued at $21,325.14 to AmerisourceBergen Drug Corp for the supply of TAGRISSO 80 mg tablets (30-count units) with a firm fixed price arrangement. This non-set-aside contract was competitively awarded on August 25, 2025, with an ultimate completion date of September 16, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. TAGRISSO is a prescription oncology medication used in the treatment of...
- The Defense Logistics Agency awarded a delivery order valued at $10,641.07 to AmerisourceBergen Drug Corp for the supply of TAGRISSO 40 mg tablets (30-count units) under a firm fixed price contract. This delivery order, issued on July 30, 2025, with an ultimate completion date of August 20, 2025, represents a non-set-aside, competitively awarded procurement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. TAGRISSO is a prescription...
- The Defense Logistics Agency awarded a delivery order valued at $10,662.57 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count packages). This competitive award, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance of this contract will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a...
- AmerisourceBergen Drug Corp received a delivery order award from the Defense Logistics Agency (DLA) on September 18, 2025, for TAGRISSO 80 mg tablets (30-count units) with a ceiling value of $10,662.57. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $42,650.28 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on September 12, 2025, with completion expected by October 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tagrisso is an oncology medication used in the treatment of non-small cell lung cancer,...
- The Defense Logistics Agency awarded a delivery order valued at $10,662.57 to AmerisourceBergen Drug Corp for TAGRISSO 80 mg tablets (30-count units) on September 3, 2025, with completion scheduled for September 24, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical...
- The Defense Logistics Agency awarded a $21,282.14 delivery order to AmerisourceBergen Drug Corp for TAGRISSO 40 mg tablets (30-count units) on August 19, 2025, with an ultimate completion date of September 10, 2025. This non-set-aside, firm fixed-price contract represents a delivery order under the company's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a $42,650.28 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of October 7, 2025, with performance to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used in the treatment of certain lung cancers, and this award...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJF24Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $85,300.56 to AmerisourceBergen Drug Corp for TAGRISSO 80 mg tablets (30-count units) on August 4, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. TAGRISSO is an oncology medication used for treating certain types of lung cancer, reflecting the breadth of pharmaceutical products that AmerisourceBergen supplies to federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen maintains an extensive portfolio of competitively awarded contracts supporting military and veteran healthcare systems. The underlying IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of brand-name and generic drugs, vaccines, and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $85.3k | 8/4/25 |